JP2015522617A - タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体 - Google Patents

タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体 Download PDF

Info

Publication number
JP2015522617A
JP2015522617A JP2015523185A JP2015523185A JP2015522617A JP 2015522617 A JP2015522617 A JP 2015522617A JP 2015523185 A JP2015523185 A JP 2015523185A JP 2015523185 A JP2015523185 A JP 2015523185A JP 2015522617 A JP2015522617 A JP 2015522617A
Authority
JP
Japan
Prior art keywords
compound
alkyl
compound according
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015523185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522617A5 (https=
Inventor
ウラシドロ、ウォルフガング
Original Assignee
ニューロポア セラピーズ，インコーポレイティド
ニューロポア セラピーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロポア セラピーズ，インコーポレイティド, ニューロポア セラピーズ，インコーポレイティド filed Critical ニューロポア セラピーズ，インコーポレイティド
Publication of JP2015522617A publication Critical patent/JP2015522617A/ja
Publication of JP2015522617A5 publication Critical patent/JP2015522617A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015523185A 2012-07-16 2013-07-16 タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体 Pending JP2015522617A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672239P 2012-07-16 2012-07-16
US61/672,239 2012-07-16
PCT/US2013/050719 WO2014014937A1 (en) 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation

Publications (2)

Publication Number Publication Date
JP2015522617A true JP2015522617A (ja) 2015-08-06
JP2015522617A5 JP2015522617A5 (https=) 2016-09-01

Family

ID=49949212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015523185A Pending JP2015522617A (ja) 2012-07-16 2013-07-16 タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体

Country Status (15)

Country Link
US (1) US9284309B2 (https=)
EP (1) EP2872143B1 (https=)
JP (1) JP2015522617A (https=)
KR (1) KR20150031481A (https=)
CN (1) CN104703604A (https=)
AU (1) AU2013290361A1 (https=)
BR (1) BR112015001096A2 (https=)
CA (1) CA2877983A1 (https=)
ES (1) ES2661394T3 (https=)
HK (1) HK1210598A1 (https=)
IL (1) IL236712A0 (https=)
IN (1) IN2015DN01171A (https=)
MX (1) MX2015000618A (https=)
RU (1) RU2015104962A (https=)
WO (1) WO2014014937A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505779A (ja) * 2014-01-29 2017-02-23 ニューロポア セラピーズ インコーポレイテッド タンパク質凝集の阻害剤としてのヘテロアリールアミド

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
US10913735B2 (en) 2017-01-26 2021-02-09 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
WO2018138085A1 (en) * 2017-01-26 2018-08-02 Ucb Biopharma Sprl Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
CN110167937B (zh) 2017-01-26 2022-03-29 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的二环双-杂芳基衍生物
EP3589616A1 (en) 2017-02-28 2020-01-08 Universitat Autònoma de Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂
WO2025223458A1 (zh) * 2024-04-23 2025-10-30 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084642A1 (en) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369076A1 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
ATE335737T1 (de) * 2000-09-15 2006-09-15 Vertex Pharma Isoxazole und ihre verwendung als erk-inhibitoren
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
WO2010125082A1 (en) 2009-04-30 2010-11-04 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US9198891B2 (en) * 2010-05-21 2015-12-01 New York University Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084642A1 (en) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505779A (ja) * 2014-01-29 2017-02-23 ニューロポア セラピーズ インコーポレイテッド タンパク質凝集の阻害剤としてのヘテロアリールアミド

Also Published As

Publication number Publication date
ES2661394T3 (es) 2018-03-28
RU2015104962A (ru) 2016-09-10
EP2872143B1 (en) 2017-12-13
IN2015DN01171A (https=) 2015-06-26
EP2872143A1 (en) 2015-05-20
KR20150031481A (ko) 2015-03-24
MX2015000618A (es) 2015-04-10
US9284309B2 (en) 2016-03-15
EP2872143A4 (en) 2015-12-02
WO2014014937A1 (en) 2014-01-23
CN104703604A (zh) 2015-06-10
AU2013290361A1 (en) 2015-02-05
HK1210598A1 (en) 2016-04-29
CA2877983A1 (en) 2014-01-23
US20150183776A1 (en) 2015-07-02
IL236712A0 (en) 2015-02-26
BR112015001096A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
JP2015522617A (ja) タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体
US11078196B2 (en) Heteroaryl amides as inhibitors of protein aggregation
CN110198938B (zh) 作为蛋白质聚集调节剂的双-杂芳基衍生物
US10975066B2 (en) Bis-heteroaryl derivatives as modulators of protein aggregation
JP6159388B2 (ja) タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体
CN110191885B (zh) 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
CN103958484B (zh) 噁唑烷酮类衍生物、其制备方法及其在医药上的应用
CA3048947C (en) Bis-heteroaryl derivatives as modulators of protein aggregation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180403